Amgen Inc., the world's largest biotechnology company, and Tularik Inc., a pioneer in drug discovery related to cell signaling and the control of gene e
The results of a long-term clinical trial on a new drug designed to inhibit the progression of type I diabetes was announced at the International Diabetes Society meeting in Cambridge, England, March 29. The findings of the 18-month long clinical trial
BioSante Pharmaceuticals, Inc. has announced the publication of positive results of a preclinical study of its proprietary calcium phosphate nanoparticle (CAP) delivery system for the oral deliv
HHS Secretary Tommy G. Thompson today urged people with Medicare to take advantage of real savings on their prescription medicines by signing up for Medicare-approved drug discount cards. The cards offer savings of 10 to 25 percent or more for beneficia
Genencor International, Inc. today announced that it has agreed to sell its therapeutic vaccine program to Belgian biotechnology company Innogenetics N.V. Innog
Early yesterday morning, two Medicare beneficiaries visited Kroger pharmacies in the Cincinnati area and received the first prescription discounts delivered by the Pharmacy Care Alliance under the Medicare prescription discount card program.
Drugs approved for treatment of specific maladies sometimes show unexpected benefits. Researchers at the 95th annual meeting of the American Association for Cancer Research demonstrated highlighted how some drugs may one day offer previously unforeseen ben
Genentech, Inc. and Roche have announced that the New England Journal of Medicine published the first Phase III study of an anti-angiogenesis cancer therapy, showing that th
A drug designed to cut off a tumor's blood supply, when paired with a chemotherapy combination, resulted in significant improvement in survival in patients with metastatic colorectal cancer, the first time in decades that survival times have been extended
Solvay has re-evaluated the commercial potential of bifeprunox, a Solvay compound in clinical development for the treatment of schizophrenia . Bifeprunox additionally has the potential to be developed in other disorders, i.e.
"As doctors, we are concerned by the news that ibuprofen and other NSAIDs may cause heart attacks. This is one in a line of recent reports that seem to show serious side effects linked to painkillers used by millions of people with arthritis around the world. This case is particularly worrying since many of these medicines are available without a prescription in many countries.
In order to try to settle this question once and for all, full disclosure of all data - including industry safety data - is essential. Only then can decisions on whether or not to prescribe particular classes of drugs can be made on the basis of proper information. People who are sick with arthritis already have enough to worry about without having to juggle the seemingly endless stream of conflicting reports on drug side effects.
Until this is available, doctors and patients together need to consider individual risk factors related to the cardiovascular and gastrointestinal systems when deciding which types of drugs to use. Patients need to be able make informed decisions about their treatment, and doctors and pharmacists need to be sure that they are in full possession of the facts relating to drug safety. The protection of the public?s health is paramount and the pharmaceutical industry should take the necessary steps to play its part."
http://eular.org/